RT Journal Article
T1 Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
A1 Gutierrez, Antonio
A1 Bento, Leyre
A1 Novelli, Silvana
A1 Martin, Alejandro
A1 Gutierrez, Gonzalo
A1 Queralt Salas, Maria
A1 Bastos-Oreiro, Mariana
A1 Perez, Ariadna
A1 Hernani, Rafael
A1 Cruz Viguria, Maria
A1 Lopez-Godino, Oriana
A1 Montoro, Juan
A1 Piñana, Jose Luis
A1 Ferra, Christelle
A1 Parody, Rocio
A1 Martin, Carmen
A1 Español, Ignacio
A1 Yañez, Lucrecia
A1 Rodriguez, Guillermo
A1 Zanabili, Joud
A1 Herrera, Pilar
A1 Varela, Maria Rosario
A1 Sampol, Antonia
A1 Solano, Carlos
A1 Caballero, Dolores
K1 CAR-T cell therapy
K1 Acute graft-versus-host disease
K1 Allogeneic stem-cell transplantation
K1 Graft-versus-lymphoma effect
K1 Mantle cell lymphoma
K1 Non-relapse mortality
K1 Target therapy
AB Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
PB MDPI
SN 2072-6694
YR 2022
FD 2022-05-27
LK http://hdl.handle.net/10668/20899
UL http://hdl.handle.net/10668/20899
LA en
NO Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Queralt Salas M, et al.  Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. Cancers (Basel). 2022 May 27;14(11):2673
DS RISalud
RD Jul 4, 2025